Explore evidence

Gold tier: mechanically validated evidence, with its primary source.

14 evidence items · page 1 / 1

54.5 %Among women without HIV, 54.5% reported prior cervical cancer screening.

Botswanacancer du col de l'utérusobserved February 2022-July 2023PubMeddocument of 11 observations

38.3 %Among women who had never been screened, 38.3% reported lack of prioritization as a barrier to cervical cancer screening.

Botswanacancer du col de l'utérusobserved February 2022-July 2023PubMeddocument of 11 observations

Cervical cancer is the leading cause of cancer deaths among women in Botswana.

Botswanacancer du col de l'utérusPubMeddocument of 11 observations

12 %Among women who had never been screened, 12.0% reported service provision issues as a barrier to cervical cancer screening.

Botswanacancer du col de l'utérusobserved February 2022-July 2023PubMeddocument of 11 observations

17 %Among women who had never been screened, 17.0% reported lack of awareness as a barrier to cervical cancer screening.

Botswanacancer du col de l'utérusobserved February 2022-July 2023PubMeddocument of 11 observations

67.2 %Of 2994 women included in the study, 67.2% reported prior cervical cancer screening.

Botswanacancer du col de l'utérusobserved February 2022-July 2023PubMeddocument of 11 observations

3.8 %Diabetes prevalence was 3.8% in Botswana in 2014.

Botswanadiabète (non précisé)observed 2014HAL · Unilimdocument of 120 observations

80 %Among women with HIV, 80.0% reported prior cervical cancer screening.

Botswanacancer du col de l'utérusobserved February 2022-July 2023PubMeddocument of 11 observations

63 %In Botswana, the overall linkage to treatment improved from 63% to 94%.

BotswanaVIH/sidapublished 2021BMC health services researchPubMeddocument of 5 observations

27.1 %Only 27.1% of 2905 women correctly identified hrHPV as the cause of cervical cancer.

Botswanacancer du col de l'utérus · hrHPVobserved February 2022-July 2023PubMeddocument of 11 observations

26.3 %La prévalence de la neuropathie chez les personnes vivant avec le VIH au Botswana était de 26,3 % en 2018.

BotswanaVIH/sidaobserved 2018HAL · Unilimdocument of 747 observations

The prevalence of high-risk HPV genotypes was statistically higher in the Botswana population compared to Kenya (p-value < 0.001).

Botswana · Kenyainfection à HPVpublished 2022BMC infectious diseasesPubMeddocument of 4 observations

22 %Dans une étude hospitalière au Botswana, 22 % des femmes avaient une hypertension.

Botswanahypertension artérielleHAL · Unilimdocument of 602 observations

17 %Among women who had never been screened, 17.0% reported fear as a barrier to cervical cancer screening.

Botswanacancer du col de l'utérusobserved February 2022-July 2023PubMeddocument of 11 observations

Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.